BAYERS HEART SURGERY MEDICATION LEAD TO LAWSUITS

Trasylol Lawsuit
Trasylol doubles the risk of renal failure and stroke and also increases the risk of heart failure or heart attack by 55%

Trasylol is a drug approved by the FDA for use in 1993 to control bleeding in patients undergoing open heart surgery and to reduce the need for blood transfusions. The drug works by blocking enzymes that dissolve blood clots. A study published by the New England Journal of Medicine in January 2006 shows that Trasylol (aprotinin) increases the risk of kidney failure following heart surgery by more than 2.5 times (259%). The study also shows that cheaper alternatives to Trasylol are as effective in limiting blood loss but do not increase the risk of kidney damage.

Many people who were given Trasylol do not know they received it, and medical records need to be reviewed to find out if it was administered.

The manufacturer of the drug, Bayer AG based in Leverkusen, Germany, and its U.S. subsidiary with offices in suburban Pittsburgh, Pennsylvania, insist that the study in the New England Journal is flawed, and that the drug is safe.

If you or a loved has suffered from kidney failure (renal failure), heart attack, brain damage, now on dialysis, or even death following open heart surgery, you may be entitled to compensation for your medical expenses, pain and suffering, and more. Contact our service today to get in touch with experienced Trasylol attorneys to discuss your case. A Trasylol attorney has the resources and knowledge necessary to help you protect and maximize your legal rights